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Abstract 
We report the case of a 59-year-old female who developed facial edema together with 
hypoproteinemia. On the basis of 99mTc-human serum albumin scintigraphy and 
α1-antitrypsin clearance, she was diagnosed with protein-losing gastroenteropathy. 
Furthermore, she was diagnosed with Sjögren syndrome on the basis of eye and oral 
dryness, positive result with anti-SSA antibody, and salivary gland biopsy. Her symptoms 
improved with the use of immunosuppressive agents following steroid pulse therapy. 
Therefore, steroid pulse therapy and immunosuppressive agents should be considered as 
possible effective treatment strategies for protein-losing gastroenteropathy associated 
with autoimmune diseases. 
Introduction 
Protein-losing gastroenteropathy (PLGE) is a disease that induces excessive plasma 
protein loss from digestive organs into the gastrointestinal (GI) tract. Causes of PLGE 
include primary diseases, such as Ménétrier disease or intestinal lymphangiectasia and 
secondary diseases that develop along with other diseases [1]. Although several reports Case Rep Gastroenterol 2011;5:372–377 
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have been published recently on PLGE associated with collagen diseases [2–5], it is 
relatively rare for PLGE to develop together with Sjögren syndrome (SS). Few patients 
with SS require steroid pulse or immunosuppressive therapy because of resistance to the 
moderate or high amounts of steroid, as in this case. Here we report a patient who 
achieved remission with steroid pulse and immunosuppressive therapies.  
Case Report 
The patient was a 59-year-old female with a medical history of rheumatoid arthritis developed at the 
age of 40 and Hashimoto thyroiditis developed at the age of 51. Since a few years, she has been free from 
rheumatoid arthritis symptoms such as morning stiffness, fatigue, and joint pain, and on examination 
active arthritis was absent. She noticed facial edema around March 2010 and was referred to our 
hospital in April 2010 for further examination and treatment.  
At admission her height was 153.2 cm, weight was 74.4 kg, body temperature was 35.8°C, blood 
pressure was 121/90 mm Hg, and she had a regular pulse rate of 72/min. Furthermore, no cardiac 
murmurs or pulmonary rales were heard, and edema on the upper eyelids and lower legs with pitting 
was observed. Laboratory findings at admission including levels of total protein and albumin were 
5.9 g/dl and 2.8 g/dl, respectively, suggesting hypoproteinemia. Urinalysis showed a positive result (+1) 
for urinary protein. However, the quantitative urinary protein was 34.2 mg/dl, and no abnormal protein 
leakage into the urine was observed. Hepatic and renal functions were normal. Thyroid hormones were 
controlled within the normal range (TSH 2.812 μIU/ml, FT3 1.71 pg/ml, and FT4 1.23 ng/dl) with 
100 μg/day levothyroxine sodium. The level of the anti-thyroglobulin antibody was 1,630 U/ml and that 
of the anti-microzome antibody was positive at a dilution of 1:1,280. The levels of complement C3 and 
C4 were 35.6 mg/dl (normal 75–130 mg/dl) and 20 mg/dl (normal 16–31 mg/dl), respectively. Serum 
IgG level was 658 mg/dl (normal 932–1,976 mg/dl), and stool fat was detected by Sudan III staining. 
Chest X-ray on admission revealed a right-sided pleural effusion, and an echocardiogram revealed a 
pericardial effusion, although no abnormality was found in cardiac function.  
After admission, the patient was concomitantly treated with intravenous albumin infusion and 
diuretic injection (fig. 1), and further examinations were performed to detect the cause of her 
symptoms. Upper and lower GI endoscopic examinations were performed to find the cause of protein 
leakage from the digestive organs. Upper GI endoscopy revealed mild swelling of the entire gastric 
mucosa without any tumor or erosive ulcerative lesions or giant folds such as those manifested in 
Ménétrier disease and other conditions. Although the mucosal surface appeared normal, lower GI 
endoscopy revealed mild edema and congestion of the entire colon; however, no tumor formation or 
erosive ulcerative lesion was observed. 
99mTc-human serum albumin (
99mTc-HSA) scintigraphy revealed 
early radioisotope accumulation in the stomach (fig. 2) and α1-antitrypsin (α1-AT) clearance was high 
at 205 ml/day (normal <13 ml/day), and thus a diagnosis of PLGE was made.  
Furthermore, complication of her condition by SS was suspected because she had eye and oral 
dryness for more than a month before admission. Using the gum test, 23 ml of saliva was collected and 
Schirmer’s test results were 6 and 8 mm for the right and left eyes, respectively. According to the 
diagnostic criteria for SS in Japan, diagnosis of SS was confirmed by a positive result for anti-Ro/SSA 
antibodies (anti-Ro/SSA antibody level was 355 U/ml and anti-La/SSB antibody level was <7 U/ml) and 
salivary gland biopsy. 
The diagnosis of PLGE complicated by SS was made as described above and 50 mg/day prednisolone 
(PSL) was administered (fig. 1). However, treatment was not successful. Hypoproteinemia was 
aggravated with total serum protein at 2.8 g/dl and albumin at 1.0 g/dl, and worsening of edema and 
development of diarrhea were observed. Therefore, steroid pulse therapy (1.0 g/day methylprednisolone 
for 3 days) was initiated as an alternative treatment. The levels of total serum protein and albumin 
increased and facial edema and digestive tract symptoms disappeared. The dose of PSL was tapered off 
after reducing it to 60 mg/day. However, a flare-up was observed. We obtained informed consent from 
the patient and performed steroid pulse therapy for the second time together with cyclophosphamide 
(CPA) pulse therapy and oral administration of 150 mg/day mizoribine (MZR). No relapse occurred, 
and she was discharged when her total serum protein and albumin had been maintained at nearly 
normal levels. After treatment, radioisotope accumulation previously observed in 
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scintigraphy disappeared and α1-AT clearance improved to 17.3 ml/day with reduced protein loss from 
the digestive organs into the GI tract. In addition, upper and lower GI endoscopies revealed 
disappearance of intestinal edema.  
Discussion 
PLGE is a disease that induces excessive loss of plasma proteins into the GI tract. The 
causes of PLGE include various diseases such as digestive tract diseases, cardiac diseases, 
or collagen diseases. For autoimmune PLGE, the number of reports regarding PLGE cases 
associated with collagen disease has been increasing in Japan [3–5], especially after the 
study of Pachas et al. in 1971 of systemic lupus erythematosus (SLE) complicated by 
PLGE [2]. Primary collagen diseases include SLE – which is observed most commonly –, 
mixed connective tissue diseases, SS and scleroderma [3].  
To the best of our knowledge, from 1986 until 2010, only 22 cases of PLGE associated 
with SS were reported in Japan (including minutes in a conference and our case) [3, 5]. 
Among these, 86.4% of patients, including our case, were females with a mean age of 
45.3 years. In most cases (90.9%), edema was the main symptom and digestive tract 
symptoms, such as diarrhea, were rare (22.7%). PLGE has recently been diagnosed using 
99mTc-HSA scintigraphy. The most common site of protein loss, if detectable, is the small 
intestine. Protein loss from the stomach, as presented in this case, is rare; only 4 cases 
have been reported until date. The mean α1-AT clearance was 219.1 ml/day; the level was 
likely to be higher than the 100 ml/day in PLGE cases that developed repeatedly along 
with inflammatory bowel disease with mucosal disorders [6]. 
Upper GI endoscopic examination performed before treatment revealed neither 
giant folds at the greater curvature of the body of the stomach nor viscous gastric fluid 
secretion as that manifested in Ménétrier disease, indicating that abnormality in the 
mucosal surface was absent. Furthermore, lymphangiectasia was not detected in biopsies 
of the stomach and duodenum, from where protein loss was suspected.  
The mechanisms of protein loss from the GI wall involve abnormality of the 
intestinal lymphatic system [7], increased papillary permeability [8], or abnormality 
of gastric mucosal epithelium [9]. However, the exact mechanism responsible for PLGE 
in association with collagen disease remains unclear. A majority of the GI endoscopic 
findings in previously reported cases were edematous changes of lesions with a very mild 
redness, and the biopsy findings were often mild inflammatory cell infiltration and mild 
lymphangiectasia. 
With regard to pathological observations, deposition of immunoglobulins and 
complement components, such as C3, were observed with immunostaining on the 
capillary walls in the lamina propria. It has been reported that complement activation 
may induce increased capillary permeability [3, 4, 10] resulting in protein loss. In this 
case, deposition of IgG, C3, C1q, and fibrinogen was detected on submucosal capillaries 
during immunostaining of biopsy samples having no lymphangiectasia, suggesting that 
the condition was induced by increased capillary permeability.  
With regard to treatment methods, all 22 patients with PLGE associated with SS have 
been reported to be treated with steroid therapy [3, 5]. Among the available data, in 
13 cases, the patients were treated with moderate to high levels of steroid and the Case Rep Gastroenterol 2011;5:372–377 
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treatment was effective in 10 patients (76.9%). Thus, the outcome was relatively 
satisfactory. However, in the present case, the patient was resistant to high levels of 
steroid (50 mg/day PSL) and required steroid pulse therapy (fig. 1, point A). Although 
steroid pulse therapy was partially effective, it did not adequately improve symptoms 
in our patient (fig. 1, point B). Finally, her symptoms improved with the use of 
immunosuppressive agents (CPA pulse therapy and oral administration of MZR) that 
followed the two-fold steroid pulse therapy; the steroid dose was eventually reduced. 
Therefore, more aggressive immunosuppression may increase the overall response of 
patients with PLGE associated with collagen disease resistant to a moderate to high dose 
of PSL. In some cases, it has been reported that CPA pulse therapy or administration of 
oral azathioprine (AZA) was effective in autoimmune PLGE cases associated with mixed 
connective tissue disease or SLE [11, 12].  
CPA is an alkylating agent and the most widely used agent in this class. Although it has 
been used in various non-neoplastic autoimmune diseases, some reports have shown an 
association of immunosuppressive drugs with an increased risk of hematological and 
lymphoreticular malignancies [13]. Thus, patients must be informed of these potential 
side effects. We employed intravenous CPA pulse therapy to treat patients because some 
reports have suggested the efficacy of this therapy for PLGE associated with SLE [14]. In 
addition, other reports suggest that treatment of PLGE with a combination of PSL and 
AZA is effective and well tolerated by the patients [12]. 
We used MZR (an imidazole nucleoside), which has frequently been used instead 
of AZA as a component of immunosuppressive drug regimens (renal transplantation 
patients, severe lupus nephritis, steroid-resistant nephritic syndrome, and rheumatoid 
arthritis patients). Furthermore, the efficacy of MZR for ameliorating glandular 
symptoms has been reported through improvements in immune abnormalities in patients 
with SS [15].  
We present the first report of a patient with PLGE associated with SS that shows a 
favorable therapeutic effect of MZR. This patient showed improvement with the use of 
CPA pulse therapy, and consequently, MZR followed the steroid pulse therapy. Therefore, 
the dose of the steroid administered could be reduced. She has been free from facial 
edema as well as hypoproteinemia and has maintained complete remission after the 
combination therapy of low-dose PSL and MZR. 
We suggest that a combination of immunosuppressive agents may be effective in 
patients with PLGE-associated autoimmune diseases. However, these treatments are still 
controversial and to support efficacy require more evidence with regards to the types of 
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Fig. 1. Clinical course during hospitalization. PSL = Prednisolone; M-PSL = methylprednisolone; 
CPA = cyclophosphamide; MZR = mizoribine. Parameters indicate total protein (Ɣ) and albumin (Ŷ). 
PSL (50 mg/day) was administered after the diagnosis of PLGE. However, hypoproteinemia was 
aggravated with total serum protein at 2.8 g/dl and albumin at 1.0 g/dl (point A). Although steroid 
pulse therapy was partially effective, it did not adequately improve symptoms (point B). The patient’s 
symptoms improved with the use of CPA pulse therapy, and consequently, oral administration of MZR 





99mTc-HSA scintigraphy. Accumulated radioactivity was detected in areas of the stomach 
(arrows) 60 min after the intravenous injection of 
99mTc-HSA. 
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